19th Conference on Retroviruses and Opportunistic Infections Seattle, WA March 5

Conference Reports for NATAP


19th Conference on Retroviruses and Opportunistic Infections Seattle, WA March 5 - 8, 2012

	CROI 2012: "The Long & Winding Road of HIV Complications" - (04/04/11) Metabolics, Inflammation, Complications, and Aging at CROI - written by David Alain Wohl, MD - The University of North Carolina - (04/03/11) Clinical Pharmacology at CROI 2012 PrEP, HCV, Cure(residual replication in reservoirs), TB-dolutegravir, orally inhaled steroids, GS-7340, older age CSF ART levels, TDF levels/bone/renal - written by - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center - (03/27/11) CROI Summary 2012 Inflammation, metabolic complications and strategies for eradication. - written by Pablo Tebas University of Pennsylvania (03/26/11) HIV Latency and Eradication at CROI 2012 -written by David Margolis, MD University of North Carolina - (03/19/11) CROI Report: Bones, Frailty, and Vitamin D -written by Todd Brown, MD, PhD Associate Professor of Medicine Division of Endocrinology and Metabolism Johns Hopkins University - (03/19/11) CROI 2012: HIV Persistence, Latency and Eradication - written by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY (03/19/11) Antiretroviral Therapy at CROI - PHASE III, PHASE II, PHASE I -written by Joseph Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/19/11) Summary from CROI 2012 for Hepatitis Co-infection HCV direct acting antivirals (DAAs) demonstrated to work in HIV/HCV coinfection: so how are treatment paradigms in HIV/HCV coinfection changing now? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/19/11) 19th Conference on Retroviruses and Opportunistic Infections Report: prevention/PrEP, eradication, the brain, new HIV antiretroviral drugs - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine - (03/16/11) CROI 2012: Studies on Inflammation in HIV - written by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (03/16/11) NeuroAIDS at CROI 2012 - written by David Alain Wohl, MD - The University of North Carolina - (03/16/11) Renal Update CROI 2012 -written by Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine - (03/14/11) HIV Prevention at CROI 2012 - written by Jared Baeten, MD PhD, Connie Celum, MD MPH, University of Washington - (03/14/11) HIV Infection Is Associated with Greater Amounts of Non-Calcified Coronary Artery Plaque: the Multicenter AIDS Cohort Study (MACS) - (04/04/11) Intima Media Thickness Is Associated with Residual Plasma Viremia in Treated Patients with Controlled HIV Infection - (04/03/11) Higher Levels of Interleukin-6 and Soluble Tumor Necrosis Factor-Alpha Receptor I are Associated with Increased Coronary Atherosclerotic Plaque in the Multicenter AIDS Cohort Study (MACS) - (04/03/11) Progression of Atherosclerosis: Understanding RAGE (Receptor for Advanced Glycation Endproducts): NWCS 332 - (04/03/11) The Association of Race with Death from AIDS in Continuous HAART Users in the Women's Interagency HIV Study (WIHS): Being Black, death, depression, history of illicit drug use & non-adherence are all associated - (04/03/11) Rate and Predictors of Carotid Intima Media Thickness Progression in ARV-Naïve HIV-Infected and Uninfected Adults: A 48-Week Prospective Matched Cohort - (04/02/11) Ultrasonographic Measures of Cardiovascular Disease Risk in a Modern Cohort of Antiretroviral Treatment (ART)-Naïve Individuals with HIV Infection: Baseline Results from ACTG Study 5260s - (04/02/11) Subclinical Carotid Atherosclerosis Is Related to HIV Infection and Low Adherence to a Mediterranean Diet - (04/02/11) Comprehensive Cardiac Magnetic Resonance Reveals HIV is Associated with a High Burden of Myocardial Disease - (04/02/11) HIV/HCV Co-Infection: Untreated Epidemic in Urban Miami - (04/02/11) In HIV/HCV Co-infected Patients, Higher Levels of 25infected 25-Hydroxyvitamin D Were Not Associated with HCV Treatment Responses, but Were Associated wit with Ritonavir Use - (04/02/11) Augmentation of Interferon signaling pathway by Nitazoxanide: A therapeutic strategy for HIV/HCV Coinfected Relapsers to Peg-interferon and Ribavirin therapy. - (04/02/11) Nitazoxanide (NTZ) may Mitigate the Unfavorable Association between IL28B Genotype and Hepatitis C Virus (HCV) Treatment Response to Pegylated Interferon- based (PEG) therapy - (04/02/11) Safety and Anti Anti-HCV Activity of Rescue Therapy with Intravenous Silibinin (LEGALON ) in Cirrhotic HIV/HCV-infected Subjects - (04/02/11) D:A:D Sees No Link Between Atazanavir and Myocardial Infarction or Stroke - (03/30/11) Kidney Function in D:A:D With TDF, ATV, and LPV - (03/30/11) Comparison of Gut-Associated Lymphoid Tissue HIV RNA and DNA Levels in HIV-infected Controllers, Non-controllers, and HAART-suppressed Individuals: 'Untreated non-controllers have reservoir....lymphoid tissues are an active reservoir of HIV in controllers.....treatment should be considered for these individuals' - (03/26/11) Hyperparathyroidism Associated with Vitamin D Deficiency in HIV-Infected Adults - (03/26/11) CROI Summary 2012 Inflammation, metabolic complications and strategies for eradication. - written by Pablo Tebas University of Pennsylvania (03/26/11) HIV Replication, Inflammation, and the Effect of Starting Antiretroviral Therapy on Plasma Asymmetric Dimethylarginine (ADMA), A Novel Marker of Endothelial Dysfunction (HAART Improves Endothelial Dysfunction Marker ADMA which in the general pop is associated with CVD & mortality) - (03/26/11) HAART Reduces Endothelial Activation: Asymmetric dimethylarginine (ADMA) concentrations decrease in patients with HIV infection under antiretroviral therapy - (03/26/11) Lower CD4+ Counts and Detectable HIV Viral Load are Associated With Elevated Levels of ADMA in HIV+ Patients - (03/26/11) Vitamin D deficiency may impair CD4 recovery among Women's Interagency HIV Study (WIHS) participants on HAART - (03/26/11) ADMA Levels are Associated With Elevated Pulmonary Artery Pressure in HIV-Infected Individuals - (03/26/11) Morphine Induction of HIV Co-receptors and its Role in HIV Disease Progression - (03/26/11) Gut Epithelial Barrier Dysfunction, Inflammation, and Coagulation Predict Higher Mortality during Treated HIV/AIDS - (03/26/11) Gender Difference in Mucosal Integrity Impacts Response to HAART in HIV Infection - (03/26/11) Effect of Combined Antiretroviral Therapy (cART) on Bacterial Translocation, Inflammation, Coagulation and Immune Activation in Advanced (<100 CD4+ cells/mm3) Antiretroviral-Naïve Patients at Week 48 (EFV or Reyataz/r) - (03/26/11) Gut Epithelium is an Early Target of the Virus in the SIV Model of AIDS - (03/26/11) Immune activation in HIV-1 patients experiencing transiently detectable viremia during antiretroviral treatment - (03/26/11) CD4+ T Cells and Th17 Cells Repopulation in ART-Treated HIV-Infected Individuals - (03/26/11) Gut Mucosa T Lymphocyte Restoration in Chronically HIV+ Patients Treated with Recombinant Interleukin-7 - (03/26/11) Probiotic Supplementation of ARV Treatment during SIV Infection of Pigtail Macaques Results in Enhanced GI Tract CD4+ T Cell Frequency and Immunological Function - (03/26/11) Impact of Switching from Zidovudine/Lamivudine to Tenofovir/Emtricitabine on Bone Mineral Density and Bone Metabolism in Virologically Suppressed HIV-1+ Patients: A Sub-study of the PREPARE Study - (03/26/11) OLDER AGE IS ASSOCIATED WITH HIGHER ANTIRETROVIRAL CONCENTRATIONS IN CEREBROSPINAL FLUID IN HIV-INFECTED INDIVIDUALS - (03/26/11) Peripheral Neuropathy in ART-experienced Patients: Prevalence and Risk Factors - (03/23/11) CNS Penetration Effectiveness of cART and Neuropsychological Outcomes: Cross-sectional Results from the OHTN Cohort Study - (03/23/11) Microbial Translocation Independently Predicts Future Hypertension in HIV-Infected Individuals - (03/23/11) HIV Status, Burden of Comorbid Disease and Biomarkers of Inflammation, Altered Coagulation and Microbial Translocation-VA Study: important study because it finds cd4 & viral load & comorbid conditions independently associated with inflammation - (03/23/11) Improved Low Bone Mineral Density and Bone Turnover Markers with Switch from Tenofovir to Raltegravir in Virologically Suppressed HIV-1+ Adults at 48 Weeks: The TROP Study - (03/22/11) Changes in Inflammation and Endothelial Activation Markers in ARV-naïve Subjects Randomized to Abacavir/Lamivudine or Tenofovir/Emtricitabine along with Efavirenz or Atazanavir/ritonavir: AIDS Clinical Trials Group A5224s, a Sub-study of ACTG A5202 - (03/22/11) The Impact of Elevated and Pre-hypertensive Systolic Blood Pressure and the Risk of Acute Myocardial Infarction in HIV+ and HIV- Veterans - (03/22/11) Early On-treatment Responses to Telaprevir Are Lower, but Do Not Differ Significantly between HIV/HCV Co-infected and HCV Mono-infected Patients - (03/20/11) ACEi or HMG-CoA Reductase Inhibitor (Statin) Treatment as Adjunct Therapy for Persons with HIV infection: A Pilot Study - (03/20/11) Changes in Cardiovascular Biomarkers in Subjects Switching from Ritonavir- Boosted Protease Inhibitors to Raltegravir: The SPIRAL Study - (03/20/11) Longitudinal analysis of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy - (03/20/11) End-Stage Renal Disease Up in Whites, Down in Blacks in 22-Year German Study - written by Mark Mascolini - (03/19/11) Untreated Depression and Refusing ART Common in Seattle-Area HIV+ Deaths - written by Mark Mascolini - (03/19/11) NNRTI Treatment Breaks Boost Risk of Resistant HIV RNA in Female Genital Tract - written by Mark Mascolini - (03/19/11) Pharmacokinetics of Dolutegravir in Subjects With Moderate Hepatic Impairment - (03/19/11) Pharmacokinetics of a Dolutegravir Pediatric Granule Formulation in Healthy Adult Subjects - (03/19/11) Interferon-alpha & Inflammation: interferon stimulates activation/inflammation, therapies to quell activation - (03/19/11) Incomplete HIV Control During ART Triples Risk of non-Hodgkin Lymphoma - written by Mark Mascolini - (03/16/11) Oral Cancer Rate Higher With HIV--Lower CD4s Implicated in People Over 49 - written by Mark Mascolini - (03/16/11) Glucose-Lowering Drugs May Limit Progression to Symptomatic Peripheral Neuropathy - written by Mark Mascolini - (03/16/11) Antiretrovirals May Cut Neurosyphilis Risk and Improve Response to Neurosyphilis Therapy - written by Mark Mascolini - (03/16/11) Cardiovascular Risk Tied to MRS-Defined Brain Injury in 45-and-Older Men With HIV - written by Mark Mascolini - (03/16/11) Over Half of HIV+ 60 and Older Have Cognitive Deficit in San Francisco Study - written by Mark Mascolini - (03/16/11) Higher CMV Antibody Linked to Lower CD4 Nadir and Worse Neurocognitive Function - written by Mark Mascolini - (03/16/11) Sub-100 Latest CD4 Count Tied to Stroke and Cardiovascular Disease in D:A:D - written by Mark Mascolini - (03/16/11) Pilot Study Explores ACE Inhibitor and Statin as Anti-inflammatory Therapy for HIV - written by Mark Mascolini - (03/16/11) Associations between Anatomic Fat Depots with Total, Calcified, Non-Calcified and Mixed Coronary Plaque in the Multicenter AIDS Cohort Study (MACS) - (03/16/11) The Effect of a Local "Universal Antiretroviral Therapy" Policy on HIV RNA levels among Patients Entering Care with a CD4 Count Greater than 500/μl in a Public Health Clinic Setting - (03/16/11) Impact of HAART Initiation on Immune Regulation (activation/senescence) in Aging HIV-infected Women -Women's Interagency HIV Study - (03/16/11) Metformin Prevented CAC Progression But Lifestyle Modification Did Not - (03/16/11) Higher CMV Antibody Linked to Lower CD4 Nadir and Worse Neurocognitive Function - written by Mark Mascolini - (03/15/11) Cerebrospinal Fluid Concentrations of Key Antiretrovirals Increase With Age - written by Mark Mascolini - (03/15/11) Predictors of Overall and Late-Onset Lab Abnormalities With Contemporary Regimens - written by Mark Mascolini - (03/15/11) Virologic Impact of Starting ART Above 500 CD4s at San Francisco General Hospital - written by Mark Mascolini - (03/15/11) Drop in Transmitted Drug Resistance May Have Stopped in UK After 2005: may be increasing except for NNRTIs - written by Mark Mascolini - (03/15/11) Respiratory Disease May Be Underdiagnosed in Men With HIV - written by Mark Mascolini - (03/15/11) HIV Independently Raises Risk of Ischemic Stroke in 4300-Person US Study - written by Mark Mascolini - (03/15/11) "Asymptomatic" HIV Neurocognitive Impairment Not So Benign After All? - written by Mark Mascolini - (03/15/11) Elvitegravir-Containing Quad Noninferior to Atazanavir Regimen at 48 Weeks - written by Mark Mascolini - (03/15/11) TDF/FTC and TDF Alone Slash HIV Risk in Partners PrEP HIV-Discordant Couples - written by Mark Mascolini - (03/15/11) Longer D-Drug Exposure and Higher Glucose Boost Risk of Steatosis Progression - written by Mark Mascolini - (03/15/11) IFN/RBV Treatment for HCV is Associated with Development of Hypophosphatemia in HIV/HCV Co-Infected Patients! - (03/14/11) Frailty Predicts Mortality in a Cohort of HIV-Infected and At-Risk Injection Drug Users: being HIV+ & frail increased mortality risk 8-fold in this group - (03/14/11) David Margolis, UNC researchers find cancer drug that may help fight HIV - (03/14/11) Zinc Fingers 'Cure' Therapy - (03/14/11) HEPATITIS C INCIDENCE IN THE SWISS HIV COHORT STUDY: A CHANGING EPIDEMIC - (03/14/11) Biomarkers of Microbial Translocation and Macrophage Activation Are Associated with Progression of Atherosclerosis in HIV Infection: ACTG NWCS 332/A5078 Study - (03/14/11) HIV Incidence in Women at Risk for HIV Acquisition in the United States: HPTN 064 (ISIS Study): 5x higher HIV rates in USA women of color than CDC estimates, comparable to HIV rates in sub-Saharan Africa. Webinar Update see details below. - (03/14/11) Safety, Tolerability, and PK of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily with Rifampin - Results of a Phase 1 Study among Healthy Volunteers - (03/11/11) Relationship between combination of baseline viral load and CD4 cell count, and Week 48 or 96 responses to rilpivirine (RPV)or efavirenz (EFV) in treatment-naïve HIV-1-infected adults: pooled analysis from the Phase III ECHO and THRIVE trials - (03/11/11) Effect of Statin Therapy on Reducing the Risk of Serious Non-AIDS-Defining Events and Non-Accidental Death in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) Cohort - (03/11/11) Frailty Predicts Mortality in a Cohort of HIV-Infected and At-Risk Injection Drug Users: being HIV+ & frail increased mortality risk 8-fold in this group - (03/11/11) Low muscle mass in HIV infected patients: prevalence, predictors and clinical implication: change in leg fat (surrogate for lipoatrophy) predicted low muscle mass, & low muscle mass predicts mortality; low muscle mass may be part of aging phenotype in HIV+ - (03/11/11) FRAILTY AND PRE-FRAILTY IN A CONTEMPORARY COHORT OF HIV-INFECTED INDIVIDUALS IN THE SUN STUDY - (03/11/11) HIV Eradication Study by David Margolis: Administration of Vorinostat, cancer drug, Disrupts HIV-1 Latency in Patients on ART - (03/11/11) Lack of Resistance Development to the HIV-1 Attachment Inhibitor BMS-626529 During Short-Term Monotherapy with its Prodrug BMS-663068 - (03/9/11) Assessment of HIV Antiretroviral Drug Interactions With the HCV NS5A Replication Complex Inhibitor Daclatasvir Demonstrates a PK Profile Which Supports Coadministration With Tenofovir, Efavirenz and Atazanavir/r - (03/9/11) Colonoscopy Spots Abnormalities in 60% of German HIV Group--and Cancer in 4% - written by Mark Mascolini - (03/9/11) Central Obesity Raises Neurocognitive Impairment Risk in US CHARTER Cohort - written by Mark Mascolini - (03/9/11) GS-7340 25 mg and 40 mg Demonstrate Greater Antiviral Activity Compared with TDF 300 mg in a 10-Day Monotherapy Study of HIV-1 Infected Patients - (03/9/11) DATA SHOW GILEAD'S QUAD REGIMEN FOR HIV NON-INFERIOR TO PROTEASEBASED REGIMEN AT 48 WEEKS IN SECOND PIVOTAL PHASE 3 STUDY - (03/9/11) Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF "Quad" Compared to Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir DF in Treatment Naive HIV-1 Infected Subjects - (03/9/11) Frailty & Muscle Loss Increase Mortality & Are Common in HIV+ - (03/9/11) Higher Death Rate With 350-499 CD4s vs 500+ in Virologic Responders - written by Mark Mascolini - (03/8/11) Low-Dose, Cell-Homing Tenofovir Prodrug Outdoes TDF in 10-Day Study - written by Mark Mascolini - (03/8/11) Not Taking Antiretrovirals Linked to 60% Higher Risk of Neurocognitive Decline in US - written by Mark Mascolini - (03/8/11) Kidney Renal Markers Signal Linked to Higher Tenofovir Plasma Levels - written by Mark Mascolini - (03/8/11) Higher Rate and Extent of Noncalcified Coronary Artery Plaque in HIV+ MACS Men - written by Mark Mascolini - (03/8/11) Quad Not Inferior to Efavirenz Combo at 48 Weeks in Phase 3 Trial - written by Mark Mascolini - (03/8/11) GILEAD'S QUAD SINGLE TABLET REGIMEN FOR HIV NON-INFERIOR TO ATRIPLA® IN PIVOTAL PHASE 3 STUDY - (03/8/11) The Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF ("Quad") Compared to Efavirenz/Emtricitabine/Tenofovir DF in Treatment Naïve HIV-1 Infected Subjects: Primary Results of Study GS-US-236-0102 - (03/8/11) Dolutegravir ViiV Integrase Inhibitor phase 2b SPRING Study 96-Week Results in Treatment-Naives - (03/8/11) Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients - (03/7/11) HCV PI Boceprevir Lowers Levels of Three Key HIV PIs - written by Mark Mascolini - (03/7/11) Poor Adherence May Explain FEM-PrEP Failure to Find Protection From HIV With Truvada - written by Mark Mascolini - (03/7/11) CD8 Activation and Naive CD4s Predict CD4 Gains Through 10 to 15 Years of ART - written by Mark Mascolini - (03/7/11) Black Women in US Have Doubled Risk of AIDS Death, Regardless of Adherence - written by Mark Mascolini - (03/7/11) HIV Risk in US Black MSM Traced to Age Issues and Care Barriers--Not to Risk Behavior - written by Mark Mascolini - (03/7/11) Adherence Critical to Protection From HIV in Partners PrEP Trial of TDF and TDF/FTC - written by Mark Mascolini - (03/7/11) Rectal Tenofovir Gel Clears Hurdle of Safety and Acceptability Study - written by Mark Mascolini - (03/7/11) Over Half of US HIV+ People in Care Are Sexually Active, But Most Take Precautions - written by Mark Mascolini - (03/7/11) Studies Disagree on Danger in Detectable Viral Load Under 50 Copies - written by Mark Mascolini - (03/7/11) Slower Virologic Response in Pregnant Women Starting ART in France - written by Mark Mascolini - (03/7/11) Tenofovir PrEP Reduces HIV Transmission Risk By Up To 99%: Adherence Critical to Protection From HIV in Partners PrEP Trial of TDF and TDF/FTC - written by Mark Mascolini - (03/7/11) CDC: HIV Rate in Young US MSM Twice Higher Than in Sub-Saharan Africa - written by Mark Mascolini - (03/7/11) Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: SVR12 Interim Analysis - (03/7/11) GS-7977 + Ribavirin in HCV Genotype 1 Null Responders: Results from the ELECTRON Trial - (03/7/11) PHARMACOKINETIC INTERACTION BETWEEN THE HCV PROTEASE INHIBITOR BOCEPREVIR AND RITONAVIR-BOOSTED HIV-1 PROTEASE INHIBITORS ATAZANAVIR, LOPINAVIR, AND DARUNAVIR - (03/7/11) The Pharmacokinetic Interactions of HCV Protease Inhibitor TMC435 with Rilpivirine, Tenofovir, Efavirenz or Raltegravir in Healthy Volunteers - (03/7/11) Evaluation of NS3 Amino Acid Variants in a Phase 1b Study of GT 1 Infection with the HCV Protease Inhibitor, MK-5172 - (03/7/11) Influence of the HCV Protease Inhibitor Boceprevir on the Pharmacokinetics of the HIV Integrase Inhibitor Raltegravir - (03/7/11) The Effect of CD4+ T-Cell Count on Cardiovascular Risk in Treated HIV Disease - (03/7/11) Suppression of Formation Threatens Delayed-Phase Bone Loss in Virologically Suppressed HIV-infected Individuals on Chronic ART - (03/7/11)